Gilead Sciences (0QYQ) Share Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QYQ Analyst Ratings

Strong Buy

19 Buy

4 Hold

0 Sell

Based on 23 analysts giving stock ratings to

Gilead

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QYQ Stock 12 Month Forecast

Average Price Target

$129.14

▲(4.28% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $129.14 with a high forecast of $145.00 and a low forecast of $100.00. The average price target represents a 4.28% change from the last price of $123.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"80":"$80","113":"$113","146":"$146","96.5":"$96.5","129.5":"$129.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$129.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[80,96.5,113,129.5,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.07,114.60307692307691,117.13615384615385,119.66923076923077,122.20230769230768,124.73538461538462,127.26846153846154,129.80153846153846,132.33461538461538,134.8676923076923,137.40076923076924,139.93384615384616,142.46692307692308,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.07,113.38307692307691,114.69615384615383,116.00923076923075,117.32230769230769,118.63538461538461,119.94846153846153,121.26153846153845,122.57461538461537,123.88769230769229,125.20076923076923,126.51384615384615,127.82692307692307,{"y":129.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.07,111.14153846153846,110.21307692307691,109.28461538461538,108.35615384615384,107.4276923076923,106.49923076923076,105.57076923076923,104.6423076923077,103.71384615384615,102.78538461538461,101.85692307692308,100.92846153846153,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":81.119,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.963,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.486,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.989,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.372,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.024,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.762,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.646,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 72,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.901,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.11,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.624,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$145.00

Average Price Target$129.14

Lowest Price Target$100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Courtney Breen

Bernstein

$135

Buy

9.01%

Upside

Reiterated

10/21/25

Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)

Mohit Bansal

Wells Fargo

$140

Buy

13.05%

Upside

Reiterated

10/20/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Matthew Biegler

Oppenheimer

$128

Buy

3.36%

Upside

Reiterated

10/20/25

Gilead Sciences (GILD) Gets a Buy from Oppenheimer

Tim Anderson

Bank of America Securities

$140

Buy

13.05%

Upside

Reiterated

10/17/25

Bank of America Securities Remains a Buy on Gilead Sciences (GILD)

Veda Pharmyne

TR | OpenAI - 4o

$131→$135

Buy

9.01%

Upside

Upgraded

10/16/25

AI Generated ArticleAI Generated Article

Geoff Meacham

Citi

$125→$135

Buy

9.01%

Upside

Reiterated

10/10/25

Citi Remains a Buy on Gilead Sciences (GILD)

Carter Gould

Cantor Fitzgerald

$129→$135

Buy

9.01%

Upside

Reiterated

10/09/25

Gilead price target raised to $135 from $129 at Cantor FitzgeraldGilead price target raised to $135 from $129 at Cantor Fitzgerald

Brian Abrahams

RBC Capital

$98→$100

Hold

-19.25%

Downside

Reiterated

10/08/25

RBC Capital Reaffirms Their Hold Rating on Gilead Sciences (GILD)RBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $100.00 (from $98.00) while maintaining a Sector Perform rating.

Joseph Stringer

Needham

$133

Buy

7.40%

Upside

Reiterated

10/06/25

Gilead Sciences: Strategic Diversification and Promising Inflammation Pipeline Justify Buy Rating

Terence Flynn

Morgan Stanley

$143

Buy

15.47%

Upside

Reiterated

10/06/25

Gilead Sciences: Strategic Positioning and Extended Patent Protection Justify Buy Rating

Tyler Van Buren

TD Cowen

$110→$115

Buy

-7.14%

Downside

Reiterated

10/03/25

Gilead Sciences (GILD) Gets a Buy from TD Cowen

Chris Schott

J.P. Morgan

$145

Buy

17.09%

Upside

Reiterated

10/03/25

Simon Baker CFA

Rothschild & Co Redburn

$136→$143

Buy

15.47%

Upside

Reiterated

09/12/25

Redburn Atlantic Sticks to Their Buy Rating for Gilead Sciences (GILD)

Daina Graybosch

Leerink Partners

$114

Buy

-7.95%

Downside

Reiterated

09/02/25

Positive Long-Term Outlook for Gilead Sciences' PrEP Franchise Driven by Descovy's Performance and Favorable Policy Environment

Evan Seigerman

BMO Capital

$130

Buy

4.97%

Upside

Reiterated

08/21/25

Gilead Sciences (GILD) Receives a Buy from BMO Capital

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Courtney Breen

Bernstein

$135

Buy

9.01%

Upside

Reiterated

10/21/25

Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)

Mohit Bansal

Wells Fargo

$140

Buy

13.05%

Upside

Reiterated

10/20/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Matthew Biegler

Oppenheimer

$128

Buy

3.36%

Upside

Reiterated

10/20/25

Gilead Sciences (GILD) Gets a Buy from Oppenheimer

Tim Anderson

Bank of America Securities

$140

Buy

13.05%

Upside

Reiterated

10/17/25

Bank of America Securities Remains a Buy on Gilead Sciences (GILD)

Veda Pharmyne

TR | OpenAI - 4o

$131→$135

Buy

9.01%

Upside

Upgraded

10/16/25

AI Generated ArticleAI Generated Article

Geoff Meacham

Citi

$125→$135

Buy

9.01%

Upside

Reiterated

10/10/25

Citi Remains a Buy on Gilead Sciences (GILD)

Carter Gould

Cantor Fitzgerald

$129→$135

Buy

9.01%

Upside

Reiterated

10/09/25

Gilead price target raised to $135 from $129 at Cantor FitzgeraldGilead price target raised to $135 from $129 at Cantor Fitzgerald

Brian Abrahams

RBC Capital

$98→$100

Hold

-19.25%

Downside

Reiterated

10/08/25

Joseph Stringer

Needham

$133

Buy

7.40%

Upside

Reiterated

10/06/25

Gilead Sciences: Strategic Diversification and Promising Inflammation Pipeline Justify Buy Rating

Terence Flynn

Morgan Stanley

$143

Buy

15.47%

Upside

Reiterated

10/06/25

Gilead Sciences: Strategic Positioning and Extended Patent Protection Justify Buy Rating

Tyler Van Buren

TD Cowen

$110→$115

Buy

-7.14%

Downside

Reiterated

10/03/25

Gilead Sciences (GILD) Gets a Buy from TD Cowen

Chris Schott

J.P. Morgan

$145

Buy

17.09%

Upside

Reiterated

10/03/25

Simon Baker CFA

Rothschild & Co Redburn

$136→$143

Buy

15.47%

Upside

Reiterated

09/12/25

Redburn Atlantic Sticks to Their Buy Rating for Gilead Sciences (GILD)

Daina Graybosch

Leerink Partners

$114

Buy

-7.95%

Downside

Reiterated

09/02/25

Positive Long-Term Outlook for Gilead Sciences' PrEP Franchise Driven by Descovy's Performance and Favorable Policy Environment

Evan Seigerman

BMO Capital

$130

Buy

4.97%

Upside

Reiterated

08/21/25

Gilead Sciences (GILD) Receives a Buy from BMO Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

1 Month

xxx

Success Rate

23/34 ratings generated profit

Average Return

+2.91%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 67.65% of your transactions generating a profit, with an average return of +2.91% per trade.

3 Months

xxx

Success Rate

25/34 ratings generated profit

Average Return

+4.03%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.53% of your transactions generating a profit, with an average return of +4.03% per trade.

1 Year

Chris SchottJ.P. Morgan

Success Rate

18/20 ratings generated profit

Average Return

+24.23%

reiterated a buy rating 20 days ago

Copying Chris Schott's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +24.23% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+54.31%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +54.31% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QYQ Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QYQ has received 40 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. 0QYQ average Analyst price target in the past 3 months is 129.14.

Each month's total comprises the sum of three months' worth of ratings.

0QYQ Financial Forecast

0QYQ Earnings Forecast

Next quarter’s earnings estimate for 0QYQ is $2.15 with a range of $2.02 to $2.37. The previous quarter’s EPS was $2.01. 0QYQ beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0QYQ has Preformed in-line its overall industry.

0QYQ Sales Forecast

Next quarter’s sales forecast for 0QYQ is $7.46B with a range of $7.28B to $7.82B. The previous quarter’s sales results were $7.06B. 0QYQ beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0QYQ has Preformed in-line its overall industry.

0QYQ Stock Forecast FAQ

What is GB:0QYQ’s average 12-month price target, according to analysts?

Based on analyst ratings, Gilead Sciences’s 12-month average price target is 129.14.

What is GB:0QYQ’s upside potential, based on the analysts’ average price target?

Gilead Sciences has 4.28% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Gilead Sciences a Buy, Sell or Hold?

Gilead Sciences has a consensus rating of Strong Buy, which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.

What is Gilead Sciences’s share price target?

The average share price target for Gilead Sciences is 129.14. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $145.00 ,and the lowest forecast is $100.00. The average share price target represents 4.28% Increase from the current price of $123.84.

What do analysts say about Gilead Sciences?

Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of Gilead Sciences?

To buy shares of GB:0QYQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Gilead Sciences (0QYQ) Share Forecast & Price Target

0QYQ Analyst Ratings

0QYQ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gilead Sciences

0QYQ Analyst Recommendation Trends

0QYQ Financial Forecast

0QYQ Earnings Forecast

0QYQ Sales Forecast

0QYQ Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts